¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Interleukin-1 Receptor Accessory Protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • histamine receptor
    È÷½ºÅ¸¹Î¼ö¿ëü
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin adhesion receptor
    ¸é¿ª±Û·ÎºÒ¸°ºÎÂø¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • interferon receptor
    ÀÎÅÍÆä·Ð¼ö¿ëü
  • internalization receptor
    ³»ÀçÈ­¼ö¿ëü
  • joint receptor
    °üÀý¼ö¿ë±â
  • kinesthetic receptor
    ¿îµ¿°¨°¢¼ö¿ë±â
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ë±â
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±Ù(À°)¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • olfactory receptor
    Èİ¢¼ö¿ë±â
  • opiate receptor
    ¾ÆÆíÁ¦¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • irritant receptor
    Àڱؼö¿ëü
  • receptor imaging
    ¼ö¿ëü¿µ»ó, ¼ö¿ëü¿µ»óÈ­
  • receptor internalization
    ¼ö¿ëü¼¼Æ÷³»À̵¿
  • receptor-ligand interaction
    ¼ö¿ëü¹èÀ§ÀÚ»óÈ£ÀÛ¿ë
  • joint receptor
    °üÀý¼ö¿ë±â
  • kinesthetic receptor
    ¿îµ¿°¨°¢¼ö¿ëü
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ëü
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±ÙÀ°¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • olfactory receptor
    Èİ¢¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • opioid receptor
    ¾ÆÆíÀ¯»ç¹°Áú¼ö¿ëü
  • paciniform receptor
    ÆÄÄ¡´ÏÇü¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • accessory state
    µ¡»óÅÂ
  • accessory suprarenal glands
    µ¡ºÎ½Å
  • accessory symptom
    ºÎÁõ»ó(ÜùñøßÒ).
  • accessory thymic nodule<³ª> nodulus thymici accessorii
    ºÎÈä¼±¼Ò°áÀý(ÜùýØàÍá³Ì¿ï½).
  • accessory thyroid
    ºÎ¼ö°©»ó¼±(ºÎ¼ö°©»ó¼±).
  • accessory thyroid gland
    µ¡°©»ó»ù, ºÎ°©»ó¼±(ÜùË£ßÒàÍ).
  • accessory thyroid gland
    µ¡°©»ó»ù
  • accessory uterus
    ºÎÀÚ±Ã(Üùí­Ïà).
  • accessory vertebral vein
    µ¡Ã´ÃßÁ¤¸Æ
  • accessory<³ª> accessorius
    ºÎ(Üù)ÀÇ, º¸Á¶(ÜÍð¾)ÀÇ, ºÎ(¼Ó)ǰ(ݾáÕù¡).
  • primordial accessory ligament
    ¿ø½Ãµ¡Àδë
  • pubic branch [accessory obturator vein]
    µÎµ¢°¡Áö(µ¡Æó¼âÁ¤¸Æ)
  • AA protein
    ¾Æ¹Ð·ÎÀ̵åA´Ü¹é(¡­Ó±ÛÜ)
  • ABP=> androgen-binding protein
    ¾Èµå·ÎÁ¨°áÇմܹé
  • Bence Jones protein
    º¥½º-Á¸½º´Ü¹é.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • complement receptor 1
    º¸Ã¼ ¼ö¿ëü 1
  • complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • corpuscular receptor
    ¼Òü ¼ö¿ëü
  • distance receptor
    °Å¸®¼ö¿ë±â.
  • distance receptor
    °Å¸®(Ëå×î)¼ö¿ë±â(áôé»Ðï).
  • dominant receptor
    ¿ì¼º¼ö¿ëü.
  • dominant receptor
    ¿ì¼º¼ö¿ëü(éÐàõáôé»ô÷).
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü(áôé»ô÷)
  • dopamine receptor antagonist
    µµÆÄ¹Î ¼ö¿ëü ±æÇ×Á¦
  • drug receptor
    ¾à¹°¼ö¿ëü.
  • drug receptor
    ¾à¹°¼ö¿ëü(å·Úªáôé»ô÷).
  • early receptor potential
    Á¶±â½Ã¼¼Æ÷ÀüÀ§
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • GTP-binding protein
    GTP°áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • guanine-nucleotide-binding protein
    ±¸¾Æ´Ñ´©Å¬·¹¿ÀŸÀÌµå °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • heat labile protein
    ¿­ºÒ¾ÈÁ¤ ´Ü¹éÁú
  • heat shock protein
    ¿­(æð)
  • heat stable protein
    ¿­¾ÈÁ¤ ´Ü¹éÁú
  • helix-destabilizing protein
    ³ª¼± ºÒ¾ÈÁ¤È­ ´Ü¹éÁú(Õ¢àÁÝÕäÌïÒûùÓ±ÛÜòõ)
  • heme protein
    Èû´Ü¹éÁú(Ó±ÛÜòõ)
  • high-potential iron protein
    °íÀüÀ§(ÍÔï³êÈ) ö´Ü¹éÁú(ôÑÓ±ÛÜòõ)
  • homologous protein
    µ¿Á¾´Ü¹éÁú(ÔÒðúÓ±ÛÜòõ)
  • hybrid protein
    Æ¢±â´Ü¹éÁú(Ó±ÛÜòõ)
  • hypro-protein
    ÇÏÀÌÇÁ·Î´Ü¹éÁú(Ó±ÛÜòõ)
  • incomplete protein
    ºÒ¿ÏÀü ´Ü¹éÁú(ÝÕèÇîïÓ±ÛÜòõ)
  • inside-out protein
    ³»¿ÜÀüµµ ´Ü¹éÁú(Ò®èâï´ÓîÓ±ÛÜòõ)
  • internal protein
    ³»´Ü¹éÁú(Ò®Ó±ÛÜòõ)
  • intrinsic protein
    °íÀ¯ ´Ü¹éÁú(ͳêóÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PTPN protein-tyrosine phosphatase, non-receptor
PTPRA protein-tyrosine phosphatase receptor alpha
PTPRB protein-tyrosine phosphatase receptor beta
PTPRF protein-tyrosine phosphatase receptor F
PTPRG protein-tyrosine phosphatase receptor gamma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
RPTP Receptor protein-tyrosine phosphatase
RIP Receptor interacting protein
RIP140 Receptor interacting protein 140
RPTK Receptor protein tyrosine kinases
RTK receptor protein tyrosine kinase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • volume receptor
    ¿ëÀû ¼ö¿ë±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
receptor tyrosine kinase Class of membrane receptors that phosphorylate tyrosine residues. Many play significant roles in development or cell division.
Examples: insulin receptor family, c ros receptor, Drosophila sevenless, trk family.
(18 Nov 1997)
receptor, visual The layer of rods and cones, the visual cells, of the retina.
(12 Dec 1998)
visual receptor cells The rod and cone cell's of the retina.
(05 Mar 2000)
glutamate receptor <physiology> See amino acid receptor superfamily. Glutamate receptors are implicated in many important brain functions including long-term potentiation (LTP).
at least 4 major glutamate gated ion channel subtypes are presently distinguished on pharmacological grounds, named after their most selective agonists: N methyl D aspartate (NMDA implicated in memory and learning, neuronal cell death, ischaemia and epilepsy), kainic acid (KA), quisqualate/AMPA and L 2 amino 4 phosphobutyrate (APB). A fifth subtype (APCD) trans 1 amino cyclopentane 1,3 dicarboxylate is a G-protein coupled receptor.
(18 Nov 1997)
glycine receptor <physiology> Chloride channel forming receptor. One of a family of neurotransmitter receptors with fast intrinsic ion channels.
See: amino acid receptors.
(18 Nov 1997)
peptide receptor Specific receptor for peptide neurotransmitters.
(18 Nov 1997)
chemokine receptor A molecule that receives a chemokine and a chemokine dock. Several chemokine receptors are essential co-receptors for HIV.
(12 Dec 1998)
metabotropic receptor A type of receptor that is linked to intracellular production of 1,2-diacylglycerol and inositol 1,4,5-trisphosphate.
Origin: metabolism + G. Trope, turning, inclination, + -ic
(05 Mar 2000)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
PL7a receptor-tyrosine kinase <enzyme> A member of the eph receptor tyrosine kinase subfamily; shows 80% identity with myk-1; genbank l43622
Registry number: EC 2.7.1.-
Synonym: pl7a protein
(26 Jun 1999)
Con A receptor <biochemistry> A common misuse of the term receptor. Con A binds to the mannose residues of many different glycoproteins and glycolipids and the binding is therefore not to a specific site.
It could be argued that the receptor is the Con A and cells have Con A ligands on their surfaces: certainly this would be less confusing.
(05 Jan 1998)
muscarinic acetylcholine receptor Distinct from the nicotinic ACh receptor in having no intrinsic ion channel, the receptor is formed from one protein chain with 7 transmembrane regions. The receptors produce their effect via activation of GTP-binding proteins.
(18 Nov 1997)
muscarinic receptor kinase <enzyme> Phosphorylates muscarinic acetylcholine receptors and beta-adrenergic receptors
Registry number: EC 2.7.-
Synonym: muscarinic acetylcholine receptor kinase, machr kinase
(26 Jun 1999)
presynaptic receptor <physiology> Receptors located on presynaptic terminals at synapses.
(05 Mar 1998)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á